AbCellera Biologics Inc. (ABCL)

NMS – Real Time Price. Currency in USD

9.70

-0.06 (-0.56%)

Market open: Aug 12, 2026, 10:13 AM EDT

9.31

-0.45 (-4.63%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

AbCellera Biologics Inc. (ABCL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AbCellera Biologics Inc. (ABCL)

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Videos

No Data

Press releases

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results

Search stocks

AbCellera Biologics Inc. (ABCL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AbCellera Biologics Inc. (ABCL)

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Videos

No Data

Press releases

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results